ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter

Dow Jones

Dec 25, 2025

By Nicholas G. Miller

ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration.

The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays.

It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities.

ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer.

The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

December 24, 2025 13:40 ET (18:40 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2594409967"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594409967\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594409967?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-25 02:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594409967","market":"fut","top_or_hot":-1,"title":"ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration. \n</p>\n<p>\n  The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays. \n</p>\n<p>\n  It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities. \n</p>\n<p>\n  ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer. \n</p>\n<p>\n  The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 13:40 ET (18:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuCell Pauses Investment in Cow Mastitis Drug After Receiving FDA Incomplete Letter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-25 02:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration. \n</p>\n<p>\n  The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays. \n</p>\n<p>\n  It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities. \n</p>\n<p>\n  ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer. \n</p>\n<p>\n  The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 24, 2025 13:40 ET (18:40 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ICCC","symbol_name":"伊芙美尔医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594409967","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594409967","pubTimestamp":1766601600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration.The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays.It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities.ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer.The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a re","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ICCC":"伊芙美尔医疗","BK4139":"生物科技"},"translate_title":"ImmuCell在收到FDA不完整信函后暂停投资奶牛乳腺炎药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ICCC":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  ImmuCell paused investment in its Re-Tain drug to treat mastitis in dairy cows after receiving an incomplete letter from the Food and Drug Administration. \n\n\n  The company said Wednesday the FDA is declining to approve its application for the drug because the contract manufacturer used in the filling of the product into syringes has not satisfactorily addressed inspectional deficiencies. ImmuCell said it would pause further investment in Re-Tain due to the practical implications of the resulting delays. \n\n\n  It said it would increase its investment in its First Defense franchise, which gives calves immediate immunity from certain scours pathogens. The company will boost its First Defense field sales force by 50% and expand the franchise's manufacturing capabilities. \n\n\n  ImmuCell will complete ongoing investigational studies with Re-Tain and will seek to license the product or partner with a global manufacturer. \n\n\n  The company expects a non-cash impact to profit of $2.3 million in the fourth quarter as a result of the strategic shift. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 24, 2025 13:40 ET (18:40 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}